Between 2005 and 2008 the Accord 12 trial accrued 598 patients with locally advanced rectal cancer and compared two different neoadjuvant chemoradiotherapies ( Capox 50 : capecitabine + oxaliplatin +50 Gy vs Cap 45 : capecitabine +45 Gy ) .